Please login to the form below

Not currently logged in
Email:
Password:

YM BioSciences

This page shows the latest YM BioSciences news and features for those working in and with pharma, biotech and healthcare.

Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial

Other JAK2 inhibitors coming through the pipeline for myelofibrosis include Gilead Sciences' CYT387, which it acquired as part of its $510m takeover of YM Biosciences at the end of 2012.

Latest news

  • Jakafi cleared for bone marrow disorder by FDA Jakafi cleared for bone marrow disorder by FDA

    Other JAK inhibitors coming through the pipeline include Gilead Sciences' CYT387, acquired as part of its $510m takeover of YM Biosciences at the end of 2012 and Cell Therapeutics/Baxter's

  • Feverish activity

    CIMYM (a subsidiary of YM BioSciences) is developing nimotuzumab (TheraCIM h-R3, Theraloc), an EGFR antagonist with the intent of blocking epithelial growth factor and tumour growth factor from binding to ... Another media release from YM BioSciences, in

  • Battling breast cancer

    YM Biosciences' tesmilifene is a histamine antagonist in phase III trials, which has been granted fast track status by the FDA for enhancing the activity of anthracycline chemotherapy in the treatment

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics